Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis

Review found that the primary course of 4CmenB is sufficient to achieve an immune response within 30 days of vaccination. A booster is required for children to prolong the protection against strain M10713, and long-term immunogenicity against strain NZ98/254 remains suboptimal.

The UK became the first country to include 4CMenB in the national infant immunisation programme. The UK programme uses a reduced two-dose infant priming schedule instead of the 3 + 1 schedule that is licensed in Europe.